VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwNHL 2017 | CC122: a new IMiD in the treatment of diffuse large B-cell lymphoma

John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. IMiDs have been shown to have single agent activity, particularly in lymphoma and myeloma. A novel compound being developed for diffuse large B-cell lymphoma is called CC122, shown to be well tolerated, and its administered as orally. It has also been tested in combination with a BTK inhibitor, an MTOR inhibitor, and with anti CD20 antibodies in the relapsed refractory setting. These will hopefully be put through Phase III testing in the near future.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter